RCM
RA Capital Management Portfolio holdings
AUM
$5.94B
This Quarter Return
-14.02%
1 Year Return
+18.15%
3 Year Return
+417.5%
5 Year Return
+458.13%
10 Year Return
+21,247.51%
AUM
$5.99B
AUM Growth
+$5.99B
(-20%)
Cap. Flow
-$57.7M
Cap. Flow
% of AUM
-0.96%
Top 10 Holdings %
Top 10 Hldgs %
62.92%
Holding
100
New
11
Increased
14
Reduced
4
Closed
15
Top Buys
| 1 |
Vaxcyte
PCVX
|
$132M |
| 2 |
SION
Sionna Therapeutics, Inc. Common Stock
SION
|
$109M |
| 3 |
Disc Medicine
IRON
|
$78.3M |
| 4 |
Geron
GERN
|
$48.3M |
| 5 |
89bio
ETNB
|
$41.5M |
Top Sells
| 1 |
Legend Biotech
LEGN
|
$244M |
| 2 |
SPDR S&P Biotech ETF
XBI
|
$111M |
| 3 |
Axsome Therapeutics
AXSM
|
$84.6M |
| 4 |
VRNA
Verona Pharma
VRNA
|
$82.1M |
| 5 |
Praxis Precision Medicines
PRAX
|
$58.6M |
Sector Composition
| 1 | Healthcare | 99.82% |
| 2 | Financials | 0.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ascendis Pharma
ASND
$11.8B
| $1.6B | 26.76% | 10,281,496 +168,752 | +2% | +$26.3M |
|
|
2
Vaxcyte
PCVX
$4B
| $460M | 7.69% | 12,189,149 +3,499,959 | +40% | +$132M |
|
3
Rhythm Pharmaceuticals
RYTM
$6.85B
| $322M | 5.38% | 6,084,412 | – | – |
|
4
Janux Therapeutics
JANX
$1.37B
| $302M | 5.05% | 11,189,693 +824,041 | +8% | +$22.2M |
|
5
NewAmsterdam Pharma
NAMS
$2.71B
| $208M | 3.47% | 10,138,938 +1,293,938 | +15% | +$26.5M |
|
6
Arcellx
ACLX
$3.85B
| $199M | 3.33% | 3,036,527 +249,200 | +9% | +$16.3M |
|
7
Edgewise Therapeutics
EWTX
$1.51B
| $196M | 3.27% | 8,909,091 | – | – |
|
8
Avidity Biosciences
RNA
$5.99B
| $186M | 3.11% | 6,300,408 | – | – |
|
9
Wave Life Sciences
WVE
$1.53B
| $147M | 2.46% | 18,202,009 | – | – |
|
|
10
89bio
ETNB
$1.34B
| $145M | 2.41% | 19,889,683 +5,714,285 | +40% | +$41.5M |
|
11
ARS Pharmaceuticals
SPRY
$1.15B
| $137M | 2.28% | 10,860,977 | – | – |
|
|
SION
12
Sionna Therapeutics, Inc. Common Stock
SION
$1.09B
| $109M | 1.82% | +10,445,322 | New | +$109M |
|
|
LENZ
13
LENZ Therapeutics
LENZ
$1.1B
| $107M | 1.79% | 4,178,823 | – | – |
|
14
Dyne Therapeutics
DYN
$1.92B
| $102M | 1.7% | 9,714,392 +3,333,248 | +52% | +$34.9M |
|
15
Tyra Biosciences
TYRA
$675M
| $98.9M | 1.65% | 10,637,290 | – | – |
|
16
Mineralys Therapeutics
MLYS
$1.03B
| $97.6M | 1.63% | 6,147,280 +1,296,296 | +27% | +$20.6M |
|
|
17
Geron
GERN
$893M
| $96M | 1.6% | 60,379,366 +30,369,830 | +101% | +$48.3M |
|
18
RxSight
RXST
$370M
| $94.5M | 1.58% | 3,743,018 | – | – |
|
|
BCAX
19
Bicara Therapeutics Inc. Common Stock
BCAX
$651M
| $90.6M | 1.51% | 6,955,993 | – | – |
|
|
20
Disc Medicine
IRON
$2.07B
| $78.3M | 1.31% | +1,577,106 | New | +$78.3M |
|
21
GH Research
GHRS
$837M
| $76.6M | 1.28% | 6,944,648 +257,959 | +4% | +$2.85M |
|
22
Apogee Therapeutics
APGE
$2.17B
| $58.6M | 0.98% | 1,569,491 | – | – |
|
23
Dianthus Therapeutics
DNTH
$759M
| $52M | 0.87% | 2,866,733 +1,000,333 | +54% | +$18.1M |
|
24
Zai Lab
ZLAB
$3.68B
| $46.8M | 0.78% | 1,295,040 | – | – |
|
25
Day One Biopharmaceuticals
DAWN
$769M
| $45.6M | 0.76% | 5,755,577 | – | – |
|